Sanofi (ADR) (SNY)
Develops immunology-focused medicines and vaccines across a broad international footprint.
$42.36
vs last close−0.14 (−0.34%)
In millions of USD, except per-share figures · converted from EUR at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,529 | 13,960 | 11,128 | 13,021 | 16,198 | 8,731 | 12,135 | 12,283 | 15,069 | 13,965 | 12,865 | 14,073 |
| Cost of revenue | 4,395 | 4,632 | 3,397 | 3,902 | 4,674 | 2,598 | 3,305 | 3,423 | 3,904 | 4,153 | 3,590 | 3,452 |
| Gross profit | 10,134 | 9,328 | 7,731 | 9,119 | 11,524 | 6,133 | 8,830 | 8,859 | 11,165 | 9,811 | 9,275 | 10,621 |
| 6,460 | 8,937 | 6,317 | 7,294 | 7,365 | 5,477 | 6,275 | 7,173 | 7,019 | 10,999 | 6,678 | 7,894 | |
| Research & development | 1,903 | 2,142 | 1,911 | 1,950 | 2,119 | 2,424 | 2,069 | 2,184 | 2,098 | 2,621 | 1,999 | 2,555 |
| 2,951 | 3,354 | 2,415 | 3,038 | 3,068 | 1,421 | 2,736 | 3,009 | 2,621 | 2,746 | 2,854 | 3,014 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 193 | 0 | 0 | 0 | 191 | 193 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 2,542 | 0 | 0 | 0 | 2,662 | 2,820 |
| Other expenses | 1,606 | 3,442 | 1,991 | 2,307 | 2,178 | 1,632 | 1,470 | 1,979 | 2,300 | 5,632 | 1,826 | 2,325 |
| Operating income | 3,674 | 391 | 1,414 | 1,825 | 4,159 | 656 | 2,555 | 1,686 | 4,145 | −1,188 | 2,596 | 2,728 |
| −126 | −676 | −164 | −205 | −62 | −140 | −38 | −8 | −132 | −134 | −292 | −1,780 | |
| Interest income | 164 | 321 | 168 | 296 | 152 | 212 | 98 | 177 | 130 | 27 | 69 | 88 |
| Interest expense | 364 | 336 | 283 | 348 | 303 | 346 | 244 | 230 | 260 | −115 | 204 | 328 |
| Other non-operating income | −164 | 563 | −168 | 78 | −152 | 251 | −158 | −42 | −130 | −3,305 | 101 | 1,442 |
| Income before tax | 3,548 | −285 | 1,251 | 1,620 | 4,097 | 516 | 2,517 | 1,678 | 4,014 | −1,322 | 2,304 | 947 |
| Income tax expense | 644 | 354 | 119 | 342 | 843 | 5 | 550 | 263 | 778 | −398 | 481 | 516 |
| Net income from continuing operations | 2,904 | −638 | 1,132 | 1,278 | 3,254 | 511 | 1,967 | 1,415 | 3,236 | −923 | 1,824 | 431 |
| Discontinued operations | 0 | 0 | 180 | 0 | 0 | 0 | 199 | 3,097 | −23 | 15 | 30 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 73 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 2,889 | −635 | 1,296 | 1,273 | 3,221 | 571 | 2,142 | 4,508 | 3,206 | −916 | 1,847 | 392 |
| EPS, basic | $1.14 | −$0.25 | $0.53 | $0.51 | $1.29 | $0.40 | $0.87 | $1.83 | $1.32 | −$1.69 | $0.77 | $0.16 |
| EPS, diluted | $1.14 | −$0.25 | $0.53 | $0.51 | $1.29 | $0.40 | $0.87 | $1.83 | $1.30 | −$1.67 | $0.77 | $0.16 |
| Weighted average shares, basic | 2,506 | 2,507 | 2,498 | 2,502 | 2,506 | 2,507 | 2,468 | 2,468 | 2,436 | 2,441 | 2,408 | 2,393 |
| Weighted average shares, diluted | 2,506 | 2,507 | 2,498 | 2,502 | 2,506 | 2,507 | 2,468 | 2,468 | 2,468 | 2,441 | 2,408 | 2,393 |
| EBITDA | 4,481 | 486 | 2,136 | 2,318 | 4,859 | 644 | 3,169 | 2,161 | 4,803 | 4,374 | 3,108 | 1,918 |
| Depreciation & amortization | 643 | 658 | 554 | 571 | 548 | 239 | 457 | 432 | 527 | 2,256 | 612 | 632 |
| EBIT | 3,838 | −172 | 1,582 | 1,747 | 4,311 | 405 | 2,713 | 1,729 | 4,276 | 2,118 | 2,495 | 1,286 |